{"id":"NCT02442271","sponsor":"AbbVie","briefTitle":"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil","officialTitle":"An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Treatment-Naïve or Treatment-Experienced Adults in Brazil With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ III)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04-27","primaryCompletion":"2016-07-04","completion":"2016-09-26","firstPosted":"2015-05-13","resultsPosted":"2017-08-01","lastUpdate":"2017-08-01"},"enrollment":222,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C Infection"],"interventions":[{"type":"DRUG","name":"ombitasvir/paritaprevir/ritonavir and dasabuvir","otherNames":["Viekira Pak","paritaprevir also known as ABT-450","ombitasvir also known as ABT-267","dasabuvir also known as ABT-333"]},{"type":"DRUG","name":"ribavirin","otherNames":[]}],"arms":[{"label":"3-DAA ± RBV","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the proportion of subjects achieving sustained virologic response 12 weeks post-treatment (SVR12) in adults with genotype 1 (GT1) chronic HCV infection, who received treatment with 3 direct-acting antiviral agents (3-DAAs; ombitasvir/paritaprevir/ritonavir and dasabuvir) with or without ribavirin.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","timeFrame":"12 weeks after the last actual dose of study drug","effectByArm":[{"arm":"3-DAA ± RBV","deltaMin":96.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":222},"commonTop":["HEADACHE","FATIGUE","NAUSEA","PRURITUS","ASTHENIA"]}}